The ABCB1-1Δ mutation is not responsible for subchronic neurotoxicity seen in dogs of non-collie breeds following macrocyclic lactone treatment for generalized demodicosis

Veterinary Dermatology

Volumn 20, Issue 1, 2009, Pages 60-66

  Bissonnette, Stéphane ^a   Paradis, Manon ^a   Daneau, Isabelle ^a   Silversides, David W ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

ANTIFUNGAL AGENT; GLYCOPROTEIN P; LACTONE; ORGANIC ANION TRANSPORTER;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMICALLY INDUCED DISORDER; DERMATOMYCOSIS; DOG; DOG DISEASE; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MUTATION; NUCLEOTIDE SEQUENCE; TOXICITY AND INTOXICATION;

ANIMALS; ANTIFUNGAL AGENTS; BASE SEQUENCE; DERMATOMYCOSES; DOG DISEASES; DOGS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; LACTONES; MALE; MUTATION; NEUROTOXICITY SYNDROMES; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN;

EID: 58449108025     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2008.00731.x     Document Type: Article

References (54)

1. Hadrick MK. Ivermectin toxicosis in two Australian shepherds. Journal of American Veterinary Medical Association 1995 206 : 1147 50.
2. Hopper K, Aldrich J, Haskins SC. Ivermectin toxicity in 17 collies. Journal of Veterinary Internal Medicine 2002 16 : 89 94.
3. Preston JM. Adverse reactions to unapproved applications. Veterinary Record 1983 112 : 286.
4. Seward RL. Reactions in dogs given ivermectin. Journal of American Veterinary Medical Association 1983 183 : 493.
5. Tranquilli WJ. Ivermectin toxicosis in two Australian shepherds. Journal of American Veterinary Medical Association 1995 206 : 1150.
6. Campbell WC, Benz GW. Ivermectin: a review of efficacy and safety. Journal of Pharmacology and Therapeutics 1984 7 : 1 16.
7. Beal MW, Poppenga RH, Birdsall WJ, Hughes D. Respiratory failure attributable to moxidectin intoxication in a dog. Journal of American Veterinary Medical Association 1999 215 : 1813 7.
8. Tranquilli WJ, Paul AJ, Todd KS. Assessment of toxicosis induced by high-dose administration of milbemycin oxime in collies. American Journal of Veterinary Research 1991 52 : 1170 2.
9. Yas-Natan E, Shamir M, Kleinbart S, Aroch I. Doramectin toxicity in a collie. Veterinary Record 2003 153 : 718 20.
10. Bennett DG. Clinical pharmacology of ivermectin. Journal of American Veterinary Medical Association 1986 189 : 100 4.
11. Turner MJ, Schaeffer JM. Mode of action of ivermectin. In : Campbell WC, ed. Ivermectin and Abamectin. New York : Springer-Verlag, Inc., 1989 : 73 88.
12. Wolstenholme AJ, Rogers AT. Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology 2005 131 : S85 95.
13. Lankas GR, Gordon LR. Toxicology. In : Campbell WC, ed. Ivermectin and Abamectin. New York : Springer-Verlag, Inc., 1989 : 89 112.
14. Pulliam JD, Preston JM. Safety of ivermectin in target animals. In : Campbell WC, ed. Ivermectin and Abamectin. New York : Springer-Verlag, Inc., 1989 : 149 61.
15. Paul AJ, Tranquilli WJ, Seward RL, Todd KS, DiPietro JA. Clinical observations in collies given ivermectin orally. American Journal of Veterinary Research 1987 48 : 684 5.
16. Pulliam JD, Seward RL, Henry RT, Steinberg SA. Investigating ivermectin toxicity in collies. Veterinary Medicine 1985 7 : 33 40.
17. Fassler PE, Tranquilli WJ, Paul AJ, Soll MD, DiPietro JA, Todd KS. Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive collies. Journal of American Veterinary Medical Association 1991 199 : 457 60.
18. Paul AJ, Hutchens DE, Firkins LD, Borgstrom M. Dermal safety study with imidacloprid/moxidectin topical solution in the ivermectin-sensitive collie. Veterinary Parasitology 2004 121 : 285 91.
19. Paul AJ, Hutchens DE, Firkins LD, Keehan CM. Effects of dermal application of 10,0% imidacloprid-0, 08% ivermectin in ivermectin-sensitive collies. American Journal of Veterinary Research 2004 65 : 277 8.
20. Paul AJ, Tranquilli WJ, Hutchens DE. Safety of moxidectin in avermectin-sensitive collies. American Journal of Veterinary Research 2000 61 : 482 3.
21. Campbell WC. Use of ivermectin in dogs and cats. In : Campbell WC, ed. Ivermectin and Abamectin. New York : Springer-Verlag Inc., 1989 : 245 59.
22. Chailleux N, Paradis M. Efficacy of selamectin in the treatment of naturally acquired cheyletiellosis in cats. Canadian Veterinary Journal 2002 43 : 767 70.
23. Delucchi L, Castro E. Use of doramectin for treatment of notoedric mange in five cats. Journal of American Veterinary Medical Association 2000 216 : 215 6.
24. McTier TL, Hair A, Walstrom DJ, Thompson L. Efficacy and safety of topical administration of selamectin for treatment of ear mite infestation in rabbits. Journal of American Veterinary Medical Association 2003 223 : 322 4.
25. Pagé N, de Jaham C, Paradis M. Observations on topical ivermectin in the treatment of otoacariosis, cheyletiellosis, and toxocariosis in cats. Canadian Veterinary Journal 2000 41 : 773 6.
26. Paradis M. Ivermectin in small animal dermatology. Part II: Extralabel applications. Compendium of Continuing Education for the Practicing Veterinarian 1998 20 : 459 69.
27. Paradis M, Scott DW, Villeneuve A. Efficacy of ivermectin against Cheyletiella blakei infestation in cats. Journal of the American Animal Hospital Association 1990 26 : 125 8.
28. Paradis M, Villeneuve A. Efficacy of ivermectin against Cheyletiella yasguri infestation in dogs. Canadian Veterinary Journal 1988 29 : 633 5.
29. Wagner R, Wendlberger U. Field efficacy of moxidectin in dogs and rabbits naturally infested with Sarcoptes spp., Demodex spp. and Psoroptes spp. mites. Veterinary Parasitology 2000 93 : 149 58.
30. Bensignor E, Carlotti DN. Essai de traitement de la démodé cie généralisée du chien par la moxidectine: résultats préliminaires (18 cas). Bulletin de l'Académie Vétérinaire de France 1998 71 : 345 9.
31. Garfield RA, Reedy LM. The use of oral milbemycin oxime (Interceptor®) in the treatment of chronic generalized canine demodicosis. Veterinary Dermatology 1992 3 : 231 5.
32. Johnstone IP. Doramectin as a treatment for canine and feline demodicosis. Australian Veterinary Practitioner 2002 32 : 98 103.
33. Mueller RS, Bettenay SV. Milbemycin oxime in the treatment of canine demodicosis. Australian Veterinary Practitioner 1995 25 : 122 5.
34. Mueller RS, Hastie K, Bettenay SV. Daily oral ivermectin for treatment of generalized demodicosis in 23 dogs. Australian Veterinary Practitioner 1999 29 : 132 7.
35. Paradis M, Laperrière É. Efficacy of daily ivermectin treatment in a dog with amitraz-resistant, generalized demodicosis. Veterinary Dermatology 1992 3 : 85 8.
36. Ristic Z, Medleau L, Paradis M, White-Weithers NE. Ivermectin for treatment of generalized demodicosis in dogs. Journal of American Veterinary Medical Association 1995 207 : 1308 10.
37. Paradis M. New approaches to the treatment of canine demodicosis. Veterinary Clinics of North America - Small Animal Practice 1999 29 : 1425 36.
38. Schinkel AH, Smit JJM, van Tellingen O et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994 77 : 491 502.
39. Griffin J, Fletcher N, Clemence R, Blanchfower S, Brayden DJ. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. Journal of Veterinary Pharmacology and Therapeutics 2005 28 : 257 65.
40. Mealey KL. Adverse drug reactions in herding-breed dogs: the role of P-glycoprotein. Compendium of Continuing Education for the Practicing Veterinarian 2006 28 : 23 33.
41. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the MDR1 gene. Pharmacogenetics 2001 11 : 727 33.
42. Roulet A, Puel O, Gesta S et al. MDR1-deficient genotype in collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. European Journal of Pharmacology 2003 460 : 85 91.
43. Henik RA, Kellum HB, Bentjen SA, Mealey KL. Digoxin and mexiletine sensitivity in a collie with the MDR1 mutation. Journal of Veterinary Internal Medicine 2006 20 : 415 7.
44. Sartor LL, Bentjen SA, Trepanier L, Mealey KL. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. Journal of Veterinary Internal Medicine 2004 18 : 117 8.
45. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 1996 97 (11 2517 24.
46. Nelson OL, Carsten E, Bentjen SA, Mealey KL. Ivermectin toxicity in an Australian shepherd dog with the MDR1 mutation associated with ivermectin sensitivity in collies. Journal of Veterinary Internal Medicine 2003 17 : 354 6.
47. Neff MW, Robertson KR, Wong AK et al. Breed distribution and history of canine mdr1-1Δ, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proceedings of the National Academy of Sciences of the United Sates of America 2004 101 : 11725 30.
48. Geyer J, Döring B, Godoy JR, Leidolf R, Moritz A, Petzinger E. Frequency of the nt230 (del4) MDR1 mutation in collies and related dog breeds in Germany. Journal of Veterinary Pharmacology and Therapeutics 2005 28 : 545 51.
49. Geyer J, Klintzsch S, Meerkamp K et al. Detection of the nt230 (del4) MDR1 mutation in white Swiss shepherd dogs: case reports of doramectin toxicosis, breed predisposition, and microsatellite analysis. Journal of Veterinary Pharmacology and Therapeutics 2007 30 (5 482 5.
50. Mealey KL, Northrup NC, Bentjen SA. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. Journal of American Veterinary Medical Association 2003 223 (10 1453 5.
51. Mealey KL. Therapeutic implications of the MDR-1 gene. Journal of Veterinary Pharmacology and Therapeutics 2004 27 : 257 64.
52. Mealey KL, Gay JM, Martin LG, Waiting DK. Comparison of the hypothalamic-pituitary-adrenal axis in MDR1-1Δ and MDR1 wildtype dogs. Journal of Veterinary Emergency and Critical Care 2007 17 : 61 6.
53. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Advanced Drug Delivery Reviews 2001 46 : 89 102.
54. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 1976 455 : 152 62.